Data Engine
Anchored in human reality. One of the most comprehensive spatial transcriptomics databases available today — 2,000+ patient samples and 50M+ spatially resolved cells.
Decoding Diseases with Spatial Intelligence
We marry single-cell, spatial omics, and AI to find targets the rest of the field cannot see.
THE TRANSITION
Biology happens in space
Traditional bulk approaches miss the spatial context of disease. Portrai integrates spatial biology with single-cell information to decode the architecture of the Tumor Microenvironment (TME).
- 2,000+
- Patient samples
- 50M+
- Spatially resolved cells
- 7+
- Cancer types covered
SpatialBulk
⇔
THE PORTRAI PLATFORM
One platform, Three engines A self-reinforcing flywheel
Data, prediction, and validation — each engine makes the others sharper. Every new patient sample refines our models. Every validated asset improves future target discovery.
Prediction Engine
In-silico prediction with spatial precision. TME-PK™, Vision-Gene-Language (VGL), and PortraiTME™ decode the tumor microenvironment for target and toxicity assessment.
Validation Engine
Modality-aware validation. Translate AI insights into physical assets — first computationally, then in tissue, then in vivo. ADC- and RPT-ready.
PIPELINE
Transforming insights into medicines
Advancing a robust pipeline of precision oncology assets, deeply de-risked by our spatial intelligence framework.
- 3 pre-clinical assets (POR001 · POR003 · POR006)
- Modality-aware validation across ADCs & RPTs
- Undisclosed targets — data room on request
PROGRAMMODALITYTARGETPROGRESS
- POR001 ADC Undisclosed Pre-clinical
- POR003 ADC Undisclosed In-vitro
- POR006 RPT Undisclosed In-vivo
LATEST
From the newsroom
The latest press, company news, and media coverage from Portrai.
Media Coverage - May 31, 2026
Meet Portrai, a Seoul startup mapping the human body for drug discovery
Media Coverage - Jan 15, 2026
Beyond the Main Stage: Korean Biotech Innovation at JPM Week 2026
Company News - Jan 10, 2026
Portrai announces new spatial biology patent covering TME-PK™ framework
Press Release - Dec 8, 2025
Celltrion and Portrai expand $87.75M joint R&D program to additional indications
LET'S BUILD WHAT COMES NEXT
Let's build better therapeutics, together
Partner with Portrai on spatial biology–driven drug discovery, biomarker development, or companion diagnostics.